Gabelli Funds LLC Boosts Position in Cytokinetics, Incorporated $CYTK

Key Points

• Gabelli Funds LLC raised its stake in Cytokinetics by 313.3% in Q3, adding 26,349 shares to hold 34,759 shares worth about $1.91 million.
• Analyst sentiment is bullish: 17 analysts rate CYTK a Buy (average price target $89 and an overall "Moderate Buy" consensus), with several firms recently raising targets into the mid‑$80s to low‑$100s.
• Cytokinetics is moving from development to a "high‑stakes" commercial launch of its heart drug (omecamtiv mecarbil), and recent insider option exercises and insider share sales have both supported and complicated investor sentiment.

Gabelli Funds LLC raised its holdings in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 313.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 34,759 shares of the biopharmaceutical company's stock after acquiring an additional 26,349 shares during the period. Gabelli Funds LLC's holdings in Cytokinetics were worth $1,910,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in CYTK. GABELLI & Co INVESTMENT ADVISERS INC. acquired a new position in Cytokinetics during the third quarter valued at $2,060,000. Orion Porfolio Solutions LLC acquired a new stake in Cytokinetics during the 3rd quarter worth about $617,000. GW&K Investment Management LLC purchased a new position in shares of Cytokinetics during the 3rd quarter valued at about $9,930,000. Dimensional Fund Advisors LP raised its stake in shares of Cytokinetics by 59.8% during the 3rd quarter. Dimensional Fund Advisors LP now owns 51,259 shares of the biopharmaceutical company's stock valued at $2,817,000 after buying an additional 19,173 shares during the last quarter. Finally, Legato Capital Management LLC acquired a new position in shares of Cytokinetics in the 3rd quarter valued at about $967,000.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on CYTK. Needham & Company LLC upped their target price on Cytokinetics from $84.00 to $85.00 and gave the stock a "buy" rating in a research note on Wednesday, February 25th. Royal Bank Of Canada lifted their price target on Cytokinetics from $95.00 to $101.00 and gave the company an "outperform" rating in a research report on Friday, February 20th. Jefferies Financial Group restated a "buy" rating and issued a $90.00 price objective on shares of Cytokinetics in a research report on Friday, January 9th. Morgan Stanley set a $90.00 target price on shares of Cytokinetics in a report on Thursday, January 8th. Finally, B. Riley Financial increased their target price on shares of Cytokinetics from $90.00 to $108.00 and gave the stock a "buy" rating in a research note on Wednesday, January 21st. Seventeen analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $89.00.

Trending Headlines about Cytokinetics

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: Earnings call frames a "high‑stakes" commercial launch for Cytokinetics' new heart drug — the company is shifting from development to commercialization, which can materially expand revenue if uptake meets expectations. This launch-phase narrative is the primary driver of bullish sentiment. Cytokinetics Earnings Call Marks High-Stakes Launch Phase
• Positive Sentiment: An insider exercised options worth roughly $920k+ as the heart drug hit the market — often interpreted by investors as a signal the commercial program is proceeding and that management/insiders are monetizing value created by the launch. Cytokinetics Insider Exercises Options Worth Over $920,000 as Heart Drug Hits the Market
• Neutral Sentiment: Short‑interest data reported for early March shows "0" shares — this appears to be a data error or placeholder rather than meaningful short activity, so it should not be interpreted as a shift in bearish positioning.
• Negative Sentiment: Several insiders sold shares on March 9 (CEO Robert Blum sold 7,931 shares at ~$60.72; EVP Fady I. Malik sold 2,907 shares; EVP Andrew Callos sold 2,582 shares). While each insider still holds substantial positions (sales reduced holdings by low single-digit percentages), such disclosures can be read negatively by some investors as profit-taking after the launch. CEO Form 4: CEO Form 4 — EVP Malik Form 4: Malik Form 4 — EVP Callos Form 4: Callos Form 4

Insider Activity at Cytokinetics

In other news, EVP Andrew Callos sold 2,582 shares of the business's stock in a transaction dated Monday, March 9th. The shares were sold at an average price of $60.72, for a total transaction of $156,779.04. Following the completion of the sale, the executive vice president owned 47,858 shares of the company's stock, valued at $2,905,937.76. The trade was a 5.12% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Wendell Wierenga sold 20,000 shares of the firm's stock in a transaction dated Monday, December 22nd. The shares were sold at an average price of $66.14, for a total transaction of $1,322,800.00. Following the completion of the transaction, the director directly owned 32,444 shares in the company, valued at $2,145,846.16. This represents a 38.14% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 96,113 shares of company stock worth $5,994,726 in the last ninety days. 3.40% of the stock is owned by company insiders.

Cytokinetics Price Performance

Shares of NASDAQ:CYTK opened at $64.20 on Wednesday. The business's 50 day moving average price is $64.02 and its 200-day moving average price is $60.08. Cytokinetics, Incorporated has a 1 year low of $29.31 and a 1 year high of $70.98. The firm has a market capitalization of $7.91 billion, a price-to-earnings ratio of -9.83 and a beta of 0.56.

Cytokinetics (NASDAQ:CYTK - Get Free Report) last issued its quarterly earnings results on Tuesday, February 24th. The biopharmaceutical company reported ($1.50) EPS for the quarter, missing the consensus estimate of ($1.48) by ($0.02). The company had revenue of $17.76 million for the quarter, compared to the consensus estimate of $8.02 million. The business's quarterly revenue was up 4.9% compared to the same quarter last year. During the same period in the previous year, the firm posted ($1.26) earnings per share. On average, sell-side analysts expect that Cytokinetics, Incorporated will post -5.24 earnings per share for the current year.

Cytokinetics Profile

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company's most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.

Want to see what other hedge funds are holding CYTK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.